CRI Funded Scientists

Margaret Callahan, MD, PhD, Clinical Accelerator Investigator

Memorial Sloan Kettering Cancer Center

Area of Research: Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Ovarian Cancer

Dr. Margaret Callahan is the Immunotherapeutics Program Research Director and medical oncologist at Memorial Sloan Kettering Cancer Center. She is one of the two study chairs of the clinical trial “A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab” (NCT01975831).

This study examines combinations of two checkpoint immunotherapies, in patients diagnosed with breast cancercervical cancercolorectal cancerkidney cancer, and ovarian cancer. One checkpoint inhibitor, durvalumab (Imfinzi™), blocks the PD-L1 pathway, whereas the other, tremelimumab, blocks the CTLA-4 pathway.

Additional investigators working on this trial include:

  • Antoni Ribas, MD, PhD, University of California, Los Angeles
  • Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center (Other study chair)
  • Kunle Odunsi, MD, UChicago Medicine Comprehensive Cancer Center
  • Mario Sznol, MD, Yale University
  • Patrick Dillon MD, University Virginia Health
  • Patrick Ott, MD, Dana Farber Cancer Institute
  • Reva Schneider, MD, Mary Crowley Cancer Center

Projects and Grants

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab (NCT01975831)

Memorial Sloan Kettering Cancer Center | Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Ovarian Cancer | 2013

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.